YOKOHAMA, Japan — October 7th, 2026, Taiwan Cell Manufacturing Co. (tcmc) is debuting its advanced cell manufacturing and Cell & Gene Therapy (CGT) capabilities at BioJapan 2026 from October 7–9. Located at Booth C-01, tcmc is engaging with global biotech and pharmaceutical leaders to foster high-impact international collaboration.
As a premier Asian platform for biotech matchmaking, BioJapan serves as a strategic venue for tcmc to showcase its robust expertise in GMP, CDMO, CGT, CAR-T, and Lentiviral Vector (LV) sectors, highlighting its comprehensive end-to-end services from process development to commercial manufacturing.
During the event, tcmc’s booth has attracted strong interest from multi-national industry professionals. Through on-site consultations, tcmc is addressing the global demands for CGT manufacturing and scalable CDMO models, unlocking high-potential cross-border business opportunities.
This exhibition marks a key step for tcmc to deepen its footprint in Japan and Asia, while elevating Taiwan’s profile in the global CGT sector. Moving forward, tcmc remains committed to advancing cell therapies and strengthening international networks to achieve its vision: “Rooted in Taiwan, Partnering Worldwide.”
